Safety, effectiveness and compliance study of Wepox dispopen 20000 IU in the management of Anemia due to Chronic kidney disease.

Prospective Analysis of safety, effectiveness and compliance of EPO (erythropoietin) therapy by using WEPOX® Dispopen 20,000 IU in the management of CKD Anemia - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2023/10/058943

Enrollment

1800

Registered

2023-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D631- Anemia in chronic kidney disease

Interventions

Intervention1: WEPOX Dispopen 20,000 IU of recombinant erythropoietin IP injection.: Dose 50-100 IU/Kg, 3x/week Route of administration is subcutaneous. Duration 90 days. Control Intervention1: Nil: N

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patient (age 18-75 years) of any gender. 2. Patients newly prescribed with WEPOX Dispopen 20000 IU for anemia due to chronic kidney disease (CKD). 3. Patient willing to comply with the protocol and written Informed Consent.

Exclusion criteria

Exclusion criteria: 1.Patients who do not meet requirement as per prescribing information of WEPOX Dispopen 20000 IU 2.Pregnant and lactating females

Design outcomes

Primary

Measure	Time frame
1. Incidence of adverse event 2.Incidence of serious adverse event 3. Pain at injection site 4.Discomfort at injection site Timepoint: At day 90±7	—

Secondary

Measure	Time frame
Confidence in administrationTimepoint: At day 90±7;Ease of administering accurate doseTimepoint: At day 90±7;Ease of storageTimepoint: At day 90±7;Ease of use of penTimepoint: At day 90±7;Medication ComplianceTimepoint: At day 90±7;rise in Hemoglobin (Hb) levelsTimepoint: Baseline and at day 90±7	—

Countries

India

Contacts

Public ContactDr Kokhan Debnath

Wockhardt Ltd

purushothamVS@wockhardt.com919739270420

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026